Hoth Therapeutics, Inc HOTH 深 滬
等待開盤 10-25 09:30:00 美东时间
1.395
+0.035
+2.57%
華盛通- 最 高1.40
- 今 開1.39
- 成交量 22.89万股
- 最 低 1.3474
- 昨 收 1.36
- 總市值 1849.63万
- 52周最高 3.80
- 市盈率 靜 --
- 換手率 1.73%
- 52周最低 0.6554
- 委 比 10.86%
- 總股本 1325.90万
- 歷史最高 347.00
- 量 比 0.24
- 振 幅 3.87%
- 歷史最低 0.58
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Hoth Therapeutics shares are trading higher after the company announced FDA Orphan Drug designation and preclinical data for HT-KIT in rare C-KIT-driven cancers
Hoth Therapeutics shares are trading higher after the company announced FDA Orp...
10-21 20:28
Hoth Therapeutics Prepares Presentation on October 17, 2025
Hoth Therapeutics ( ($HOTH) ) has shared an update. Hoth Therapeutics announced...
10-18 04:50
Hoth Therapeutics Expands Its AI Initiative Through Nvidia AI Enterprise Subscription License
Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling
10-08 22:24
Hoth Therapeutics To Present HT-001 And HT-KIT Oncology Programs At BIO-Europe 2025
Presentation to highlight advancements in Hoth's clinical pipeline, includingHT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology programtargeting KIT-driven tumorsNEW YORK, Oct. 7, 2025 /PRNewswire/
10-07 20:00
Hoth Therapeutics Expands Intellectual Property Portfolio For HT-001 With New U.S. Provisional Patent Filings Covering Novel Dermatological Indications
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address
09-24 20:16
Hoth Therapeutics Faces Digital Asset Industry Challenges
Hoth Therapeutics ( ($HOTH) ) has provided an announcement. The digital assets ...
09-12 20:48
Hoth Therapeutics Submits CTA To EMA To Expand Ongoing Phase II Trial Of HT-001, Topical Therapeutic For Skin Toxicities Associated With EGFRi
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing
09-10 20:32
Hoth Therapeutics shares are trading higher after the company reported its antisense therapy demonstrated efficacy against KIT-driven cancers.
Hoth Therapeutics shares are trading higher after the company reported its anti...
09-02 20:22
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
Hoth Therapeutics reported strong preclinical efficacy and safety data for HT-KIT, a precision antisense therapy targeting KIT-driven cancers.
09-02 19:46
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
08-28 19:19
